8-K filing — Benitec Biopharma Inc. (BNTC)
Filed: 2026-10-28 AccNo: 0001193125-26-435159 Size: 214 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Benitec Biopharma Announces Positive Interim Clinical Results for BB-301 in OPMD
Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301, showing robust and durable improvements in swallowing function for patients with Oculopharyngeal Muscular Dystrophy (OPMD).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Raymond James Initiates Coverage on Benitec Biopharma with Outperform Rating
Raymond James has initiated coverage on Benitec Biopharma Inc. with an "Outperform" rating and a price target of $14.00 per share.
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.